Department of Pathology


OSU Biomarker Reference Laboratory
(614) 247-6388
Contact Michael Mcgookey

Dr. Chen is director of the Biomarker Reference Laboratory (BRL), a part of clinical laboratory services here at Ohio State University Medical Center. The first goal of the BRL is to develop new clinical tests through research and innovation, and to implement these tests to improve patient care at OSUMC. It is also actively engaged in OSU’s strategic mission in personalized health care. Finally, the BRL serves as a biomarker validation site for NIKKD's Chronic Kidney Disease Biomarker Discovery and Validation Consortium (U01). So far, we have implemented three clinical tests derived from our research and innovation. They are:
  • ADAMTS13 activity assay
  • Determination of ADAMTS13 inhibitor titer
  • Monitor activation of complement system

The Biomarker Reference Laboratory at the Ohio State University Medical Center is a CAP-certified laboratory offering the following tests:
  • ADAMTS13 activity assay/ inhibitor titer
  • Activated complement biomarkers

Complement biomarkers are helpful in differentiating atypical hemolytic uremic syndrome (aHUS) from acquired Thrombotic Thrombocytopenia Purpura (TTP). Typically aHUS is a disorder characterized by dysregulated complement activity, the growth of thrombotic microangiopathy, and end organ injury.1 Patients who have this disorder have mutations on specific complement control proteins which result in uncontrolled complement activation and can lead to microthrombotic disease.2 These complement proteins include: C4d, Bb, C5a, C5b-9 and are elevated in aHUS patients. Monitoring the levels of these proteins using an enzyme-linked immunosorbent assay (ELISA) is a good indicator for the clinical diagnosis of aHUS. An objective laboratory test to confirm aHUS still remains unknown.